Sequential Pause Expected After Record Q1; Lubrizol Tie-Up in Focus
After posting best-ever quarter in Q1 FY27 with 28% revenue growth and 60% PAT surge, Garware is likely to moderate sequentially but maintain double-digit YoY growth. The Sept Lubrizol MoU on TPU films is a structural positive; margins under watch after management loss in July.
The Setup: A Pause, Not a Reversal
Garware Hi-Tech Films delivered a record-shattering Q1 FY27—₹633 Cr revenue (+28% YoY, +6% QoQ), PAT ₹133 Cr (+60% YoY, +23% QoQ), EBITDA margin 21%—a watershed quarter on both topline and bottom-line metrics. Q2 is expected to pull back sequentially but remain on-plan for double-digit growth relative to last year. The Street debate centers on three points: (1) whether the Q1 surge was a one-off volume push or sustained demand; (2) margin sustainability after the July loss of Joint MD Mrs. Sarita Garware Ramsay; and (3) upside optionality from the Lubrizol MoU signed in late September on TPU (thermoplastic polyurethane) film solutions, a new segment for the company.
~₹560–580 Cr
Sequential moderation from Q1's ₹633 Cr likely; YoY growth +15–20% anchored to H1 run-rate
~19–21%
Q1 hit record 21%; normalization to 19–20% is healthy; cost absorption and mix critical
₹100–115 Cr
Implies 10–12% YoY growth; well below Q1's 60% but consistent with mid-teen medium-term guidance
Volume vs price realization
Q1 beat was driven by both volume (+28% YoY) and pricing power; Q2 will show if demand holds or normalizes
On Track?
FY26 context: Full-year FY26 revenue was ₹2120 Cr (+0.5% YoY), a muted print signaling prior-year base effects and sector headwinds. However, Q4 FY26 and Q1 FY27 momentum reversal—with Q1 posting the highest quarterly revenue and PAT in company history—suggests a genuine demand inflection rather than one-off accounting or inventory adjustment. If Q2 comes in at the expected ₹560–580 Cr, H1 FY27 will total ~₹1200 Cr, tracking toward a full-year FY27 revenue of ₹2400+ Cr, a 12–15% increase on-year. That trajectory aligns with mid-teen CAGR medium-term guidance and is on-plan. The Lubrizol TPU partnership (inked Sept 23, 2026) is additive to this base case—development and manufacturing of TPU films opens a new market segment currently not in Garware's revenue mix, though contribution may not materialise materially until FY28.
Since Last Quarter: Key Events
Jul 09, 2026
Risk: Key decision-maker loss; leadership continuity questioned. Interim CFO appointed Aug 06 to stabilize operations.
Joint MD Mrs. Sarita Garware Ramsay passes away
Aug 06, 2026
Mitigant: Maintains financial continuity post-leadership loss. Ongoing search for permanent CFO likely.
Interim CFO appointment (Prashant L. Pai)
Sep 23, 2026
Positive: Collaboration on advanced TPU-based film solutions—new market, potential licensing/co-manufacturing upside over FY28–29.
Lubrizol MoU signed for TPU films
Sep 23, 2026
Routine: Approval of dividend for FY26, director re-elections (Ms. Monika Garware re-confirmed as Vice-Chairperson and Joint MD for five years from Nov 1, 2026).
69th AGM held
Oct 17, 2026
Q2 results to be declared Oct 22, 2026 (tomorrow).
Board meeting intimation for Oct 22 result
What a Strong vs Weak Print Looks Like
A strong Q2 print: Revenue ₹580+ Cr (YoY +18%+), EBITDA margin ≥20%, PAT ₹110+ Cr. This would signal that Q1 was not an anomaly but part of a sustained demand cycle; margin resilience despite management transition; and confidence in guidance upgrades for FY27.
A weak Q2 print: Revenue <₹550 Cr (YoY +10% or below), EBITDA margin <18%, PAT <₹95 Cr. A miss here would suggest pricing pressure, volume loss post-Q1 spike, or early signs of sectoral slowdown. It would also test the market's faith in management continuity post-July loss.
Ownership & Price Momentum
FII ownership rose to 4.22% in Q1 FY27 (from 3.98% in Q4 FY26), while DII inched up to 6.35% (from 5.27%). Promoter stake stable at 60.72%. Stock is trading below its 20- and 50-day SMAs (₹6866, ₹6941) but well above the 200-day SMA (₹5396), consistent with a pullback in an overall uptrend. RSI at 43.2 (neutral zone) suggests room for directional move post-result.
1 · Volume trajectory—Q1 vs Q2
Confirm whether Q1's 28% YoY growth was driven by sustained demand or a one-time volume push. Sequentially flat to -8% is on-plan; >-15% would signal demand weakness.
2 · Margin story post-management loss
EBITDA margin at 19–21% range validates operational stability and pricing power despite July transition. A dip below 18% would raise concerns on cost control under interim leadership.
3 · FY27 guidance and TPU partnership timeline
Management's commentary on full-year FY27 revenue/PAT guidance and expected contribution timeline from Lubrizol tie-up will set the Street narrative for Q3 and FY28 expectations.
Garware Hi-Tech Films enters Q2 on the back of a historic Q1, and the market will be listening for proof that the surge was sustainable, not a statistical blip. A sequential pullback to ₹560–580 Cr revenue is expected and healthy; the test is whether YoY growth stays north of 15% and margins hold above 19%. The Lubrizol MoU is a structural tailwind for longer-term growth, but its near-term financial impact remains unquantified. The management transition—the loss of Joint MD Mrs. Sarita Garware Ramsay in July—looms as the real risk, though the interim CFO's appointment and Ms. Monika Garware's re-confirmation as Vice-Chairperson offer some continuity. On the Street, 12–13% upside to consensus target (₹7,519) implies cautious optimism; a 20%+ PAT CAGR case is priced in at the highs. Watch for Q2 execution clarity and any forward guidance on the TPU ramp.
Result date: Oct 22, 2026 (post-market). Key metrics: Revenue, EBITDA margin, PAT. Listen for: FY27 guidance, Lubrizol timeline, CFO search status.